貴州三力(603439.SH)擬向漢方藥業增資1.119億元 持股預達25.64%
格隆匯11月20日丨貴州三力(603439.SH)公佈，基於拓展上市公司產品種類，解決公司產品相對集中的風險，提升公司行業競爭力，促進公司長遠、健康發展的戰略發展角度考慮。上市公司、盛永建、鄧代興與貴安順祺、姚廠發、貴州漢方藥業有限公司於2020年11月19日簽訂了《關於貴州漢方藥業有限公司之增資協議》，由上市公司、盛永建、鄧代興、貴安順祺共同對漢方藥業進行增資，上市公司擬現金出資1.119億元，取得漢方藥業25.64%股權，其中5679.95萬元計入註冊資本，5510.05萬元計入資本公積；盛永建擬現金出資5000.00萬元，取得漢方藥業11.46%股權，其中2537.96萬元計入註冊資本，2462.04萬元計入資本公積；鄧代興擬現金出資1億元，取得漢方藥業22.91%股權，其中5075.92萬元計入註冊資本，4924.08萬元計入資本公積；目標公司股東貴安順祺以其對漢方藥業的7000.00萬元債權轉為股權對漢方藥業增資，轉股後合計持有漢方藥業38.80%股權，其中3553.14萬元計入註冊資本，3446.86萬元計入資本公積；目標公司股東姚廠發自願放棄本次增資的優先認購權，其所持漢方藥業股權變為1.20%。
漢方藥業為貴州省內老牌藥企，藥品批文豐富，目前擁有16條GMP生產線、81個醫保產品、172個批准文號，獨家品種眾多，產品類型包括處方藥及OTC品種，涵蓋腫瘤血液類、婦科類、兒科類、慢病調理類、補益類、男科類、呼吸系統類等多個細分領域。但漢方藥業由於原股東戰略失誤和盲目擴張等原因，暴露出漢方藥業管理能力薄弱的問題，導致目前債務負擔較重，發展存在一定困難，雖然仍在生產經營，但產能利用率較低，未能充分發揮其產品優勢。
公司參股漢方藥業有利於上市公司涉足其他中成藥品種及科室，為公司帶來新的利潤增長點，增強盈利能力，緩解公司產品相對集中的風險，提升公司行業競爭力。同時，也能通過公司對醫藥製造企業的管理經驗，協助整頓目標公司現有的團隊、規範內部管理、提升治理水平、拓展商業渠道、提升產能利用率，從而增強漢方藥業的盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
